Effects of Dietary Fiber on Affective Processes

January 6, 2021 updated by: Kristin Verbeke, KU Leuven
The effects of dietary fiber on psychobiological processes are examined in a sample of healthy volunteers.

Study Overview

Status

Completed

Conditions

Detailed Description

The study is an interventional triple-blind, placebo-controlled, parallel group design with 2 arms (placebo, dietary fiber). Healthy male participants adhere to their normal eating habits for the duration of the study (32 days). At the baseline study visit, measurements are taken in the lab, including biological samples and psychophysiological measurements. Participants then consume placebo or dietary fiber for 4 weeks and revisit the lab on day 32 for a second measurement of the outcomes of interest. Specifically, we investigate the effect of dietary fiber on affective processing, including stress sensitivity and fear-related processes (e.g. extinction learning). Volunteers also respond to questionnaires in relation to mood and GI symptoms, and provide biological samples (saliva, blood, faecal, and urine samples) for analysis of cortisol levels, circulating short chain fatty acids and serum BDNF, faecal SCFA and microbiota composition, and intestinal permeability, respectively.

Study Type

Interventional

Enrollment (Actual)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • I Am Not In The U.S. Or Canada
      • Leuven, I Am Not In The U.S. Or Canada, Belgium, 3000
        • UZ Leuven/Stresslab

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 40 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Male participants
  • Age range 20-40 years
  • BMI range 18.5-27
  • Dutch or English as native-language

Exclusion Criteria:

  • previous or current neurological, psychiatric, gastrointestinal or endocrine disorders, or other relevant medical history
  • current or recent regular medication use
  • previous or current substance/alcohol dependence or abuse (> 2 units per day/14 units per week)
  • one or more diagnoses based on the mini-international neuropsychiatric interview
  • smoking
  • night-shift work
  • adherence to vegan or vegetarian diets
  • use of pre- or probiotics within one month preceding the study
  • use of antibiotics within 3 months preceding the study
  • Habitual diet not exceeding consumption of 25 g of dietary fiber per day
  • previous experience with one of the tasks used in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Refined cereal flour
Refined cereal flour
Active Comparator: Dietary fiber
Fermentable cereal bran
Fermentable cereal bran

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stress sensitivity (cortisol)
Time Frame: through study completion, on average 1 year and 5 months
Induction of cognitive, physical, and social stress using Maastricht Acute Stress Test. Stress hormone cortisol is quantified by gathering multiple saliva samples throughout the stress induction and recovery during both pre-intervention and post-intervention visit.
through study completion, on average 1 year and 5 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stress sensitivity (subjective)
Time Frame: through study completion, on average 1 year and 5 months
Induction of cognitive, physical, and social stress using Maastricht Acute Stress Test. Participant rate how much stress, discomfort, and pain they feel on a 10-cm visual analogue scale, with higher values indicating greater stress, discomfort, and pain. This is done prior to stress induction, in the middle, and at the end at both pre- and post-intervention visits.
through study completion, on average 1 year and 5 months
Cortisol awakening response
Time Frame: through study completion, on average 1 year and 5 months
Measuring chronic stress by quantifying cortisol in morning samples (5 samples taken form the moment of waking every 15 minutes for 1 hour) on the morning of the pre- and post-intervention visits.
through study completion, on average 1 year and 5 months
Fear
Time Frame: through study completion, on average 1 year and 5 months
Exploring fear-related processes (conditioning, extinction, recall, and renewal) by means of a computerised task. Fear response is measured using skin conductance, and a skin conductance response is calculated.
through study completion, on average 1 year and 5 months
Fear (subjective)
Time Frame: through study completion, on average 1 year and 5 months
Exploring fear-related processes (conditioning, extinction, recall, and renewal) by means of a computerised task. Fear response is measured subjectively by asking participants to indicate their expectancy of an aversive stimulus.
through study completion, on average 1 year and 5 months
Positive and Negative Affect Schedule (PANAS)
Time Frame: through study completion, on average 1 year and 5 months

Assessing ratings on the subscales of PANAS, positive and negative affect. PA subscale scores range between 10-50, with higher scores indicating better outcome.

NA subscale scores range between 10-50, with higher scores indicating worse outcome.

through study completion, on average 1 year and 5 months
Depression, anxiety, and stress scales (DASS-21)
Time Frame: through study completion, on average 1 year and 5 months

Assessing ratings on the subscales of DASS-21, depression, anxiety, and stress subscales.

Higher scores on these subscales indicates a worse outcome.

Normal (depression: 0 - 4; anxiety: 0 - 3; stress: 0 - 7), Mild (depression: 5 - 6; axiety: 4 - 5; stress: 8 - 9), Moderate (depression: 7 - 10; anxiety: 6 - 7; stress: 10 - 12), Severe (depression: 11 - 13; anxiety: 8 - 9; stress: 13 - 16), Extremely Severe (depression: 14 +; anxiety: 10 +; stress: 17 +).

through study completion, on average 1 year and 5 months
Leiden Index of Depression Sensitivity-Revised (LEIDS-R)
Time Frame: through study completion, on average 1 year and 5 months
Assessing ratings on the subscales of LEIDS-R and its total score. This is a self-report on cognitive reactivity comprised of 34 items with six subscales. Hopelessness/suicidality; Acceptance/Coping; Aggression; Control/Perfectionism; Risk Aversion; Rumination.
through study completion, on average 1 year and 5 months
Gastrointestinal symptom rating scale (GSRS)
Time Frame: through study completion, on average 1 year and 5 months
Assessing ratings on the subscales of GSRS and its total score. It has 5 subscales (Reflux, Diarrhea, Constipation, Abdominal Pain, and Indigestion Syndrome). Subscale scores range from 1 to 7 and higher scores indicates a worse outcome.
through study completion, on average 1 year and 5 months
Serum SCFA
Time Frame: through study completion, on average 1 year and 5 months
Quantification of serum SCFA (μM) at pre- and post-intervention
through study completion, on average 1 year and 5 months
Faecal SCFA
Time Frame: through study completion, on average 1 year and 5 months
Quantification of faecal SCFA in samples provided at pre- and post-intervention
through study completion, on average 1 year and 5 months
Perceived Stress Scale (PSS)
Time Frame: through study completion, on average 1 year and 5 months
Assessing ratings on PSS PSS scores range between 0-40 with higher scores indicating worse outcome.
through study completion, on average 1 year and 5 months
Intestinal permeability
Time Frame: through study completion, on average 1 year and 5 months
Conducting a lactulose and mannitol test before and after the intervention
through study completion, on average 1 year and 5 months
Serum BDNF
Time Frame: 1 year and 5 months
Quantification of fasting serum BDNF levels (µg/mL)
1 year and 5 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 2, 2019

Primary Completion (Actual)

November 8, 2020

Study Completion (Actual)

November 8, 2020

Study Registration Dates

First Submitted

July 14, 2020

First Submitted That Met QC Criteria

August 19, 2020

First Posted (Actual)

August 21, 2020

Study Record Updates

Last Update Posted (Actual)

January 7, 2021

Last Update Submitted That Met QC Criteria

January 6, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • S62344

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stress

Clinical Trials on Placebo

Subscribe